A Coin1, M V Pamio1, C Alexopoulos1, S Granziera1, F Groppa2, G de Rosa2, A Girardi1, G Sergi1, E Manzato1, R Padrini3. 1. Geriatric Clinic, Department of Medicine DIMED, School of Medicine, University of Padova, 35128, Padova, Italy. 2. Clinical Pharmacology Unit, Department of Medicine DIMED, School of Medicine, University of Padova, 35128, Padova, Italy. 3. Clinical Pharmacology Unit, Department of Medicine DIMED, School of Medicine, University of Padova, 35128, Padova, Italy. roberto.padrini@unipd.it.
Abstract
PURPOSE: The purpose of the study is to evaluate whether donepezil (D) plasma concentrations and activity of CYP2D6 and CYP3A4 are associated with the therapeutic response of patients with mild to moderate Alzheimer's disease (AD). METHODS: This study comprised 54 patients affected by probable AD in therapy with D 10 mg/daily for at least 3 months. Plasma concentrations of D and its three main metabolites (6DD, 5DD, DNox) were assayed with a novel high performance liquid chromatography (HPLC) technique. Cognitive progression was assessed at baseline and at 9 months of follow-up with the mini mental state examination (MMSE). The activities of the two cytochromes involved in D metabolism-CYP2D6 and CYP3A4-were evaluated according to their metabolic ratios in plasma or urine, after test doses of probe drugs (dextromethorphan and omeprazole). RESULTS: A significant correlation was found between plasma levels of D and variations in MMSE scores after 9 months of therapy (r (2) = 0.14; p = 0.006). Neither the concentrations of D metabolites nor the metabolic ratios of CYP2D6 and CYP3A4 showed any correlations with cognitive variations. Low CYP2D6 activity and advanced age were associated with high D concentrations. Patients who were treated with CYP2D6 and P-glycoprotein (P-gp) inhibitors also had higher D plasma levels (mean difference = 19.6 ng/mL; p = 0.01) than those who were not. CONCLUSIONS: D plasma concentrations, but not cytochrome phenotyping, are associated with cognitive outcomes in AD patients.
PURPOSE: The purpose of the study is to evaluate whether donepezil (D) plasma concentrations and activity of CYP2D6 and CYP3A4 are associated with the therapeutic response of patients with mild to moderate Alzheimer's disease (AD). METHODS: This study comprised 54 patients affected by probable AD in therapy with D 10 mg/daily for at least 3 months. Plasma concentrations of D and its three main metabolites (6DD, 5DD, DNox) were assayed with a novel high performance liquid chromatography (HPLC) technique. Cognitive progression was assessed at baseline and at 9 months of follow-up with the mini mental state examination (MMSE). The activities of the two cytochromes involved in D metabolism-CYP2D6 and CYP3A4-were evaluated according to their metabolic ratios in plasma or urine, after test doses of probe drugs (dextromethorphan and omeprazole). RESULTS: A significant correlation was found between plasma levels of D and variations in MMSE scores after 9 months of therapy (r (2) = 0.14; p = 0.006). Neither the concentrations of D metabolites nor the metabolic ratios of CYP2D6 and CYP3A4 showed any correlations with cognitive variations. Low CYP2D6 activity and advanced age were associated with high D concentrations. Patients who were treated with CYP2D6 and P-glycoprotein (P-gp) inhibitors also had higher D plasma levels (mean difference = 19.6 ng/mL; p = 0.01) than those who were not. CONCLUSIONS:D plasma concentrations, but not cytochrome phenotyping, are associated with cognitive outcomes in ADpatients.
Authors: Héctor M González; Elba M Romero; Teresa de J Chavez; A Aaron Peregrina; Víctor Quezada; Carlos Hoyo-Vadillo Journal: J Chromatogr B Analyt Technol Biomed Life Sci Date: 2002-11-25 Impact factor: 3.205
Authors: Jeffrey L Cummings; David Geldmacher; Martin Farlow; Marwan Sabbagh; Daniel Christensen; Peter Betz Journal: CNS Neurosci Ther Date: 2013-03-06 Impact factor: 5.243
Authors: Kirsten M Wright; Armando Alcazar Magana; Ronald M Laethem; Caroline L Moseley; Troy T Banks; Claudia S Maier; Jan F Stevens; Joseph F Quinn; Amala Soumyanath Journal: Drug Metab Dispos Date: 2020-06-24 Impact factor: 3.922
Authors: Anna Morozova; Yana Zorkina; Olga Abramova; Olga Pavlova; Konstantin Pavlov; Kristina Soloveva; Maria Volkova; Polina Alekseeva; Alisa Andryshchenko; Georgiy Kostyuk; Olga Gurina; Vladimir Chekhonin Journal: Int J Mol Sci Date: 2022-01-22 Impact factor: 5.923
Authors: Marion Ortner; Marion Stange; Heike Schneider; Charlotte Schroeder; Katharina Buerger; Claudia Müller; Bianca Dorn; Oliver Goldhardt; Janine Diehl-Schmid; Hans Förstl; Werner Steimer; Timo Grimmer Journal: Front Pharmacol Date: 2020-05-21 Impact factor: 5.810
Authors: Timo Grimmer; Werner Steimer; Marion Ortner; Marion Stange; Heike Schneider; Charlotte Schröder; Katharina Buerger; Claudia Müller; Felix Müller-Sarnowski; Janine Diehl-Schmid; Hans Förstl Journal: Drug Des Devel Ther Date: 2020-08-11 Impact factor: 4.162